TIDMPFZ
RNS Number : 9216X
Pfizer Inc
27 February 2017
Media Relations Contact:
February 27, 2017 Joan Campion
212-733-2798
Investor Relations Contact:
Ryan Crowe
212-733-8160
It should be noted that the below was released in the U.S
February 24th, 2017
Pfizer Prices $1,065,000,000 Debt Offering
NEW YORK, N.Y., February 24 - Pfizer Inc. (NYSE: PFE) today
announced the pricing of $1,065,000,000 aggregate principal amount
of 4.20% notes due 2047. This offering is expected to be sold to
professional institutional investors in Taiwan, with application to
be made to list the notes on the Taipei Exchange.
Pfizer intends to use the net offering proceeds for general
corporate purposes, including to repay a portion of its outstanding
commercial paper.
The closing of the offering is expected to occur on March 17,
2017, subject to satisfaction of customary closing conditions.
BNP Paribas, Taipei Branch and Deutsche Bank AG, Taipei Branch
are acting as joint book-running managers for the offering.
Deutsche Bank AG, Taipei Branch, Citigroup Global Markets Inc.,
HSBC Securities (USA) Inc., Mizuho Securities USA Inc., Morgan
Stanley & Co. LLC, Standard Chartered Bank, Academy Securities,
Inc., Seibert Cisneros Shank & Co., L.L.C. and The Williams
Capital Group, L.P. are acting as structuring agents for the
offering. Each structuring agent, other than Deutsche Bank AG,
Taipei Branch, is an entity not licensed in the Republic of China,
has not offered or sold, and will not subscribe for or sell or
underwrite, any of the notes.
The offering of these securities is being made only by means of
a prospectus. Copies may be obtained by calling BNP Paribas, Taipei
Branch at 1-800-854-5674 or Deutsche Bank AG, Taipei Branch at
1-800-503-4611.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any of the notes, nor will there be
any sale of the notes in any jurisdiction in which such offer,
solicitation, or sale would be unlawful.
About Pfizer
At Pfizer, we apply science and our global resources to bring
therapies to people that extend and significantly improve their
lives. We strive to set the standard for quality, safety and value
in the discovery, development and manufacture of health care
products. Our global portfolio includes medicines and vaccines as
well as many of the world's best-known consumer health care
products. Every day, Pfizer colleagues work across developed and
emerging markets to advance wellness, prevention, treatments and
cures that challenge the most feared diseases of our time.
Consistent with our responsibility as one of the world's premier
innovative biopharmaceutical companies, we collaborate with health
care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world.
For more than 150 years, we have worked to make a difference for
all who rely on us.
Forward-Looking Statements
This press release contains forward-looking statements made
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. Such forward-looking statements involve substantial risks
and uncertainties. We have tried, wherever possible, to identify
such statements by using words such as "will," "may," "could,"
"likely," "ongoing," "anticipate," "estimate," "expect," "project,"
"intend," "plan," "believe," "target," "forecast," "goal,"
"objective," "aim" and other words and terms of similar meaning or
by using future dates in connection with any discussion of, among
other things, expectations regarding the completion of the notes
offering and the use of proceeds. A list and description of risks,
uncertainties and other matters can be found in our Annual Report
on Form 10-K for the year ended December 31, 2016, including in the
sections thereof captioned "Forward-Looking Information and Factors
That May Affect Future Results" and "Risk Factors," in our
Quarterly Reports on Form 10-Q, in our Current Reports on Form 8-K,
and in the prospectus supplement and accompanying prospectus, in
each case including in the section thereof
captioned "Risk Factors." You should understand that it is not
possible to predict or identify all such factors. Consequently, you
should not consider any such list to be a complete set of all
potential risks or uncertainties.
We cannot guarantee that any forward-looking statement will be
realized, although we believe we have been prudent in our plans and
assumptions. Achievement of anticipated results is subject to
substantial risks, uncertainties and inaccurate assumptions. Should
known or unknown risks or uncertainties materialize, or should
underlying assumptions prove inaccurate, actual results could vary
materially from past results and those anticipated, estimated or
projected. You should bear this in mind as you consider
forward-looking statements, and you are cautioned not to put undue
reliance on forward-looking statements. We undertake no obligation
to publicly update forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by law or by the rules and regulations of the Securities and
Exchange Commission (the "SEC"). You are advised, however, to
consult any further disclosures we make on related subjects in our
reports on Form 10-K, 10-Q and 8-K and our other filings with the
SEC.
# # # # #
This announcement has been issued through the Companies
Announcement Service of
The Irish Stock Exchange
This information is provided by RNS
The company news service from the London Stock Exchange
END
ISESEDFSWFWSELE
(END) Dow Jones Newswires
February 27, 2017 05:45 ET (10:45 GMT)
Pfizer (LSE:PFZ)
Historical Stock Chart
From Jan 2025 to Feb 2025
Pfizer (LSE:PFZ)
Historical Stock Chart
From Feb 2024 to Feb 2025
